Benzoyl peroxide/clindamycin low dose - Stiefel Laboratories

Drug Profile

Benzoyl peroxide/clindamycin low dose - Stiefel Laboratories

Alternative Names: Benzoyl peroxide 3%/clindamycin 1%; CLDM 1%-BPO 3% gel; Clindamycin/benzoyl peroxide; Clindoxyl ADV Gel; Duac low dose; Duac Low Dose; Duac® 3% Gel; Duac® Combination Gel; GSK 2585823; Indoxyl

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Stiefel Laboratories
  • Class Antiacnes; Antibacterials; Benzoic acids; Lincosamides; Oxidants; Small molecules
  • Mechanism of Action Keratinocyte inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 23 Jun 2015 No recent reports on development identified - Preregistration for Acne vulgaris in USA (Topical)
  • 26 Mar 2015 Registered for Acne vulgaris in Japan (Topical)
  • 04 Mar 2013 The United Kingdom's Medicine and Healthcare products Regulatory Agency recommends approval of Benzoyl peroxide/clindamycin for Acne vulgaris in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top